IQVIA Holdings Inc. ($IQV) Stock Forecast: Up 11.2% Today

What is IQVIA Holdings Inc.?

IQVIA Holdings Inc. (NYSE: IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the healthcare industry. The company operates through two segments: Commercial Solutions and Research & Development Solutions.

Why is IQVIA Holdings Inc. going up?

IQV stock is up 11.2% on May 6, 2026 14:01

• IQVIA reported strong Q1 2026 financial results, with revenue reaching $4.15 billion, an 8.4% increase year-over-year, and EPS of $1.61, beating estimates.
• The stock surged by 9.60% on May 5, driven by the company's robust performance across its segments and exceeding earnings and revenue expectations.
• Analysts maintain a positive outlook on IQV, citing AI as a key driver for its success, despite some technical sell signals and debt concerns.
• The market responded positively to IQV's strong trading day, outperforming competitors and reflecting overall bullish sentiment towards the stock.

IQV Price Chart

IQV Technical Analysis

IQV News

IQVIA (NYSE: IQV) grows Q1 2026 revenue to $4.15B and boosts EPS

IQVIA Holdings Inc. reported strong first-quarter 2026 results, achieving $4.15 billion in revenue, an 8.4% increase from the previous year, and boosting diluted earnings per share to $1.61. The growth was driven by both its Commercial Solutions and Research & Development Solutions segments, with operating cash flow reaching $618 million. The company also repurchased $552 million in common stock and maintained a significant Research & Development Solutions backlog of $34.2 billion.

https://www.stocktitan.net/sec-filings/IQV/10-q-iqvia-holdings-inc-quarterly-earnings-report-5e343899f7ca.html

IQVIA Holdings Inc Stock (IQV) Closed Up by 9.60% on May 5: Key Drivers Unveiled

IQVIA Holdings Inc (IQV) stock rose by 9.60% on May 5, driven by strong Q1 2026 financial results that exceeded earnings and revenue expectations. The company increased its full-year adjusted EPS guidance and reaffirmed revenue, showing robust performance across its Commercial Solutions and Research & Development Solutions segments, with AI cited as a key driver. Despite some technical sell signals and significant debt, analysts generally maintain a "Buy" rating for IQV.

https://www.tradingkey.com/news/market-movers/261858896-market-movers-iqv-20260505

IQVIA Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation (NYSE:IQV) 2026-05-05

IQVIA Holdings Inc. announced its Q1 2026 earnings, reporting an EPS of $2.90, which beat estimates by $0.08. The company also posted revenue of $4.15 billion, an 8.41% year-over-year increase, exceeding expectations by $51.00 million. A slide deck from their earnings call was published in conjunction with these results.

https://seekingalpha.com/article/4898786-iqvia-holdings-inc-2026-q1-results-earnings-call-presentation

Assessing Thermo Fisher Scientific (TMO) Valuation After Recent Share Price Softness

Thermo Fisher Scientific (TMO) has experienced recent share price softness, with the stock closing at $462.60 and showing negative year-to-date returns. Despite the pullback, a popular narrative by Unike suggests TMO is undervalued with a fair value of $540.27, citing resilient demand in life sciences and a recurring revenue model. However, risks such as tightening R&D budgets or acquisition integration issues could challenge this valuation.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/assessing-thermo-fisher-scientific-tmo-valuation-after-recen-3

IQVIA Holdings Inc. stock outperforms competitors on strong trading day

Shares of IQVIA Holdings Inc. (IQV) rose 9.62% to $176.42 on Tuesday, outperforming the broader market. This marked the stock's second day of gains, occurring on a strong trading day for the S&P 500 Index and the Dow Jones Industrial Average.

https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-50221fa7-a7ed5051ca49

Trending Today

Silver ($XAG) Commodity Forecast: Down 6.8% Today

Marathon Digital Holdings Inc. ($MARA) Stock Forecast: Up 6.3% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Up 5.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 6.0% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 9.8% Today

Aptiv PLC ($APTV) Stock Forecast: Up 6.2% Today

TKO Group Holdings Inc ($TKO) Stock Forecast: Up 6.9% Today

Ford Motor Company ($F) Stock Forecast: Up 5.5% Today

Lyft Inc. ($LYFT) Stock Forecast: Down 5.2% Today

Bumble Inc. ($BMBL) Stock Forecast: Down 5.3% Today

IQVIA Holdings Inc. Price History

26.01.2026 - IQV Stock was up 5.2%

• Today's positive movement for IQVIA is linked to its acquisition of drug discovery assets from Charles River Laboratories, enhancing its early-stage research offerings and drug discovery platform.
• The rally was also supported by improved investor sentiment on biotech funding and clinical activity, positioning IQVIA as a resilient business with growth opportunities.
• Despite some concerns about fundamental aspects like revenue growth and free cash flow margin, the market is optimistic about IQVIA's strong 2025 performance projections, including revenue and EPS growth, and collaborations in AI-driven research.
• Overall, IQVIA's bullish momentum reflects investor confidence in its acquisitions, financial performance, and growth potential in healthcare and biotech sectors.

13.01.2026 - IQV Stock was up 5.0%

• Despite concerns about margin compression, IQVIA's Q4 earnings call exceeded revenue expectations, leading to a positive market reaction.
• Analysts remain optimistic about IQVIA's future performance, with recent insider buying and a "Moderate Buy" rating indicating confidence in the company's growth potential.
• The company's focus on AI integration, strategic acquisitions, and addressing macroeconomic challenges demonstrates its commitment to long-term success, driving the bullish movement in its stock price today.

12.01.2026 - IQV Stock was down 8.4%

• Amid Q3 earnings strength and upbeat FY2026 guidance, IQVIA Holdings Inc. (IQV) witnessed bearish movement likely attributed to:
• Decline in share price over three years, suggesting potential misvaluation or market influences.
• A recent 26% share price plunge after financial results release, causing investor apprehension.
• Price target cuts by analysts while maintaining a "Moderate Buy" rating, reflecting market uncertainty.
• Share price drop on February 10, indicating short-term selling pressure and market volatility.

12.01.2026 - IQV Stock was down 8.3%

• Despite strong Q3 earnings and positive FY2026 guidance, IQVIA Holdings' stock dropped by 26% post-financial results, indicating investor concerns.
• The discrepancy between the company's 11% annual EPS growth and the 22% decline in share price over a three-year period suggests potential misvaluation or underlying issues impacting investor sentiment.
• The recent acquisition of a significant number of IQVIA shares by Eubel Brady & Suttman Asset Management Inc. may indicate confidence in the company's long-term prospects, though market sentiment remains cautious.
• The overall bearish trend in IQV's stock could be linked to broader challenges in the medical research sector, illustrated by negative trends in competitors such as ICON plc and Charles River Laboratories International, influencing investor sentiment industry-wide.

11.01.2026 - IQV Stock was down 5.0%

• IQVIA stock saw significant downward movement during the trading day.
• The collaboration between IQVIA and the Duke Clinical Research Institute aimed at advancing clinical research in obesity and related conditions was well-received by investors.
• Despite the upbeat response to the research partnership, the stock's decline may be linked to a decrease in ownership by Compagnie Lombard Odier SCmA, suggesting waning confidence from some institutional investors.
• The overall market outlook for IQVIA is optimistic, with analysts upholding a "Moderate Buy" consensus rating and an average price target of $239.87, indicating potential growth despite today's market performance.

10.01.2026 - IQV Stock was down 5.2%

• A strategic collaboration with the Duke Clinical Research Institute to advance clinical research in obesity and related conditions is expected to have a positive impact on the company's growth and its influence on patient therapies.
• The recent reduction in stake by Compagnie Lombard Odier SCmA and Thrivent Financial for Lutherans could have contributed to a bearish movement in the stock, potentially indicating profit-taking or a shift in investor sentiment.
• Despite surpassing earnings and revenue expectations in the last quarter and offering optimistic guidance for FY 2026, concerns regarding increased interest expenses and lowered price targets by analysts may have impacted the stock's performance.
• The general market sentiment towards IQVIA is cautiously optimistic, with a consensus rating of "Moderate Buy" and an average target price of $239.87, suggesting potential for recovery ahead.

06.03.2026 - IQV Stock was up 0.2%

• IQVIA Holdings Inc. (IQV) stock price saw a significant increase following the launch of the IQVIA.ai unified agentic AI platform in collaboration with Nvidia, aimed at enhancing operational efficiency and decision-making in the life sciences industry.
• The "Buy" rating upgrade from TD Cowen and the positive reception of the platform by top pharmaceutical companies contributed to investor optimism and drove the bullish movement in IQV's stock price.
• Aberdeen Group plc's substantial increase in stake in IQVIA Holdings Inc. and the company's strong Q4 earnings performance with exceeded EPS expectations and year-over-year revenue growth further bolstered investor confidence in IQV's future prospects.

27.01.2026 - IQV Stock was up 5.2%

• Primecap Management Co. CA reduced its stake in IQVIA Holdings Inc., but other institutional investors increased their holdings, indicating varying sentiments among investors.
• The acquisition of drug discovery assets from Charles River Laboratories is seen as a strategic move to expand IQVIA's capabilities and enhance its early-stage research offerings, potentially boosting investor confidence.
• Analysts adjusting price targets for IQV post-earnings report and re-segmentation suggest a positive outlook for the company, with some considering it a strong buy despite potential competition from AI stocks.
• Broyhill Asset Management's endorsement of IQV as a top contributor to its portfolio highlights the company's strong performance and its resilience in the face of concerns over biotech funding and clinical activity, positioning it favorably in the market.

23.03.2026 - IQV Stock was down 9.0%

• The bearish movement in IQV's stock today could be attributed to profit-taking by investors after a period of sustained growth.
• The positive news surrounding Royalty Pharma's dividend approval and partnership with Johnson & Johnson may have diverted some investor attention away from IQVIA Holdings Inc.
• The initiation of coverage by BMO Capital with an Outperform rating might have raised expectations for IQV's stock, leading to a sell-off as investors locked in profits.
• The Google Discover Core Update emphasizing personalized news feeds on IQVIA Holdings Inc. could have triggered algorithmic trading or increased volatility in the stock as investors digested the implications of the update.

05.04.2026 - IQV Stock was up 10.0%

• IQVIA reported strong first-quarter 2026 financial results, with revenue increasing by 8.4% year-over-year to $4,151 million and Adjusted Diluted Earnings per Share up by 7.4%. This positive performance was driven by strong results in both Commercial Solutions and Research & Development Solutions.
• Despite exceeding earnings and revenue forecasts, the stock initially dipped in pre-market trading due to investor concerns. This could be attributed to market volatility and increased competition in the industry.
• IQVIA's strong performance was fueled by AI solutions, new drug launches, and strategic partnerships, along with aggressive share repurchases. The company's focus on innovation and growth strategies seems to be resonating well with investors, leading to a bullish market movement for the stock.

05.04.2026 - IQV Stock was up 5.2%

• IQVIA reported strong first-quarter 2026 financial results, exceeding revenue and earnings expectations, driven by robust performance in Commercial Solutions and Research & Development Solutions.
• Despite beating forecasts and reaffirming its full-year guidance, IQV's stock initially dipped in pre-market trading due to investor concerns, possibly related to market volatility and competition worries.
• The market movement turned bullish as investors likely recognized the company's strong fundamentals, including its AI solutions, new drug launches, and strategic partnerships, leading to a positive outlook for continued growth.
• Integration of AI in life sciences operations, as highlighted in industry reports, could have also positively influenced investor sentiment towards IQVIA, showcasing the company's innovative approach and potential for further advancements in the sector.

06.04.2026 - IQV Stock was up 11.2%

• IQVIA reported strong Q1 2026 financial results, with revenue reaching $4.15 billion, an 8.4% increase year-over-year, and EPS of $1.61, beating estimates.
• The stock surged by 9.60% on May 5, driven by the company's robust performance across its segments and exceeding earnings and revenue expectations.
• Analysts maintain a positive outlook on IQV, citing AI as a key driver for its success, despite some technical sell signals and debt concerns.
• The market responded positively to IQV's strong trading day, outperforming competitors and reflecting overall bullish sentiment towards the stock.